Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MonoSol Rx and APR Applied Pharma are looking for new partners for anti-emetic Zuplenz (Ondansetron) oral soluble film, following the regaining of the product's commercial rights from Strativa Pharmaceuticals.
Subscribe to our email newsletter
Developed by using MonoSol Rx’s PharmFilm technology, Zuplenz is a film formulation that delivers either 4 or 8mgs of ondansetron.
Zuplenz helps in preventing postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.
MonoSol Rx chief technology officer and CEO Mark Schobel said Zuplenz provides patients suffering from nausea and vomiting as a result of chemotherapy or surgery with a minimally invasive and highly tolerable drug delivery form.
"We look forward to maximizing this potential with a pharmaceutical partner that can effectively detail to physicians in the sizable US market," Schobel said.